Sulbactam (Standard)
Based on 1 Customer Validation
Sulbactam (Standard) is the analytical standard of Sulbactam. This product is intended for research and analytical applications. Sulbactam (CP45899) is a competitive, irreversible beta-lactamase inhibitor. Sulbactam shows antimicrobial activity against multidrug-resistant (MDR) acinetobacter calcoaceticus--Acinetobacter baumannii (Acb) complex.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 68373-14-8
- 화학식: C8H11NO5S
- 분자량:233.24
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 68373-14-8
-
Appearance Solid
-
분자량 233.24
-
화학식 C8H11NO5S
-
Color White to light yellow
-
SMILES
O=C([C@@H](C(C)(C)S([C@]1([H])C2)(=O)=O)N1C2=O)O
-
Synonyms
CP45899 (Standard)
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Noguchi JK, et al. Sulbactam: a beta-lactamase inhibitor. Clin Pharm. 1988;7(1):37-51. [Content Brief]
[2]. Lin HS, et al. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47(6):370-378. [Content Brief]
[3]. Betrosian AP, et al. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol. 2009;5(9):1099-1112. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)